Analysis of U.S. Patent 11,160,795: Pharmaceutical Compositions and Methods of Treatment

U.S. Patent 11,160,795, granted on January 4, 2022, to Gilead Sciences, Inc., covers pharmaceutical compositions containing specific combinations of antiretroviral agents and methods of using these compositions for treating Human Immunodeficiency Virus type 1 (HIV-1) infection. The patent's claims focus on formulations that achieve desired pharmacokinetic profiles and therapeutic outcomes, particularly for patients with specific resistance mutations.

What is the Core Innovation Protected by Patent 11,160,795?

The patent claims a synergistic combination of an integrase strand transfer inhibitor (INSTI) and a nucleotide reverse transcriptase inhibitor (NtRTI) for the treatment of HIV-1. Specifically, the invention relates to compositions containing bictegravir and tenofovir alafenamide, often in combination with emtricitabine. The novelty lies in the specific pharmacokinetic and pharmacodynamic properties achieved by these combinations, leading to improved efficacy and tolerability.

Key Components:
- Bictegravir: An INSTI that inhibits the HIV-1 integrase enzyme, preventing viral DNA integration into the host cell genome.
- Tenofovir Alafenamide (TAF): A prodrug of tenofovir, an NtRTI that inhibits reverse transcriptase, an enzyme essential for viral replication. TAF is designed for more efficient delivery to target cells and reduced systemic exposure compared to older tenofovir prodrugs.
- Emtricitabine (FTC): Another NtRTI, often included in fixed-dose combinations for its complementary mechanism of action.

The patent emphasizes specific molar ratios and formulation characteristics that ensure optimal drug concentrations in plasma and target tissues, thereby enhancing antiviral activity and minimizing resistance development.

What are the Specific Claims of U.S. Patent 11,160,795?

The patent contains multiple claims defining the scope of protection. The primary claims focus on the composition itself and its therapeutic use.

Claim 1: Pharmaceutical Composition

This independent claim defines a specific pharmaceutical composition comprising:

Bictegravir: Defined by its chemical structure and often referring to its free base or a pharmaceutically acceptable salt. The claim specifies a particular amount or range, typically designed for once-daily dosing.
Tenofovir Alafenamide: Also defined by its chemical structure or salt form. The claim sets forth a specific amount or range, again optimized for daily administration.
Emtricitabine: Defined by its chemical structure or salt form, with specified amounts or ranges.

The claim also includes requirements for the composition to be formulated for oral administration and to comprise a specific combination of these active pharmaceutical ingredients (APIs) in defined proportions. The formulation is designed to achieve a plasma concentration profile that enhances efficacy and reduces toxicity.

Claim 2-20: Dependent Claims and Variations

Subsequent claims refine and narrow the scope of Claim 1, providing additional layers of protection:

Specific Dosages: Claims may specify precise milligram amounts for each API, reflecting marketed formulations. For instance, a common formulation protected by such patents includes 50 mg of bictegravir, 10 mg of tenofovir alafenamide, and 200 mg of emtricitabine per tablet.
Formulation Excipients: Claims can cover specific excipients used in the tablet formulation, such as binders, disintegrants, lubricants, and coatings, which contribute to the drug's stability, dissolution profile, and bioavailability.
Dosage Regimen: Claims may define the method of administration, such as a single tablet taken once daily.
Patient Population: Claims can specify the intended recipient, for example, an HIV-1 infected individual.
Resistance Mutations: Some claims may target the treatment of HIV-1 infection in patients with specific documented or suspected resistance mutations to other antiretroviral drug classes. This is a critical aspect as drug resistance is a major challenge in HIV treatment.
Combination Therapies: While the core invention is a fixed-dose combination, dependent claims might also encompass co-administration of these agents with other antiretroviral drugs, though the primary focus remains on the specific combination.

Method of Treatment Claims

Independent and dependent claims also cover methods of treating HIV-1 infection using the defined pharmaceutical compositions. These claims describe the act of administering the composition to a patient in need thereof.

General Treatment: Claims cover the general administration of the composition for the treatment of chronic HIV-1 infection.
Specific Regimens: Claims may delineate the dosage and frequency of administration, such as administering the composition once daily.
Treatment of Specific Viral Loads or CD4 Counts: Claims can specify treatment for individuals with particular viral loads or CD4+ T-cell counts.
Suppression of Viral Replication: Claims focus on the outcome of treatment, such as achieving and maintaining viral suppression below detectable limits.

What is the Patent Landscape Surrounding U.S. Patent 11,160,795?

The patent landscape for HIV therapeutics is highly competitive, with multiple companies holding patents on individual drugs, combinations, formulations, and methods of use. U.S. Patent 11,160,795 is part of a broader intellectual property strategy by Gilead Sciences for its successful HIV treatment regimens.

Key Players and Technologies:

Gilead Sciences: The primary assignee for U.S. Patent 11,160,795. Gilead has a dominant position in the HIV market with its integrase inhibitor-based regimens, including Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) and Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide). Patents related to these products form a complex web.
ViiV Healthcare: A joint venture of GlaxoSmithKline and Pfizer, ViiV Healthcare is another major competitor with a strong portfolio of HIV drugs, including dolutegravir (an INSTI) and abacavir. Their patents often cover INSTI-based combinations.
Merck & Co.: Known for its INSTI doravirine and its combination therapy Delstrigo.
Bristol Myers Squibb: While historically strong in nucleoside reverse transcriptase inhibitors (NRTIs), they have also been active in HIV drug development.

Related Patent Families and Technologies:

Bictegravir Patents: Gilead holds numerous patents covering the synthesis, crystalline forms, polymorphs, and specific formulations of bictegravir.
Tenofovir Alafenamide (TAF) Patents: TAF itself is covered by extensive patent protection, focusing on its prodrug mechanism, improved pharmacokinetic profile, and reduced bone/renal toxicity compared to tenofovir disoproxil fumarate (TDF).
Fixed-Dose Combination (FDC) Patents: The consolidation of multiple APIs into a single pill is a significant innovation that requires its own patent protection. These patents often claim the specific combination of drugs and the manufacturing process that allows for stable and bioavailable co-formulations.
Method of Use Patents: These patents claim the use of specific drug combinations to treat particular patient populations, such as those with baseline resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) or specific resistance mutations to INSTIs.
Polymorph Patents: Discoveries of novel crystalline forms of the active pharmaceutical ingredients (APIs) can extend patent exclusivity, as different polymorphs can have distinct physical properties (e.g., solubility, stability) impacting manufacturing and bioavailability.

Patent Expirations and Generics:

The expiration dates of key patents are critical for understanding future market competition. Patents related to the individual components (bictegravir, TAF, emtricitabine) and their combinations have staggered expiration dates. Generic manufacturers will seek to enter the market once primary patents and any extensions (e.g., Hatch-Waxman extensions) expire. U.S. Patent 11,160,795, as a method of use or composition patent related to a specific combination, is part of this larger patent expiration timeline. The strength and breadth of the claims within this patent will influence the strategies of generic challengers.

What is the Significance of This Patent for Pharmaceutical Companies?

U.S. Patent 11,160,795 is significant for several reasons, primarily relating to market exclusivity and the protection of a highly successful therapeutic regimen.

Market Exclusivity and Revenue Protection:

This patent, along with others in Gilead's portfolio, protects the commercial success of its fixed-dose combination products, particularly those containing bictegravir, emtricitabine, and tenofovir alafenamide. These products represent a substantial portion of Gilead's revenue from its HIV franchise. Extended market exclusivity through strong patent protection allows the company to recoup its significant R&D investments.

Strategic Importance of Fixed-Dose Combinations:

The development of single-tablet regimens (STRs) has revolutionized HIV treatment by improving patient adherence and simplifying treatment protocols. Patents covering these FDCs are crucial for maintaining a competitive advantage. This patent secures protection for a specific and highly effective STR.

Barriers to Entry for Competitors:

The patent acts as a legal barrier for other pharmaceutical companies seeking to market biosimilar or generic versions of the protected combination. Competitors must either wait for patent expiration, challenge the patent's validity, or develop non-infringing alternative therapies. The specific wording and scope of the claims determine the precise boundaries of this barrier.

Justification for R&D Investment:

The existence of strong patent protection incentivizes companies to invest in complex R&D projects, such as developing novel drug combinations and optimizing their pharmacokinetic profiles. The potential for extended market exclusivity justifies the substantial financial and scientific resources required to bring such therapies to market.

Licensing and Collaboration Opportunities:

While this patent is held by Gilead, the broader patent landscape can create opportunities for licensing or collaboration. However, for this specific patent, it primarily serves to reinforce Gilead's proprietary position.

What are the Potential Challenges or Weaknesses of Patent 11,160,795?

Despite its strength, any patent can face challenges. The scope and validity of U.S. Patent 11,160,795 could be tested through various legal and scientific means.

Prior Art Challenges:

The most common challenge to a patent's validity is the existence of prior art that anticipates or renders obvious the claimed invention. This could include earlier scientific publications, patents, or public disclosures that describe similar compositions or methods of treatment. Generic manufacturers often conduct extensive prior art searches to identify grounds for invalidating a patent.

Obviousness Arguments:

Even if no single piece of prior art exactly matches the claims, an argument could be made that the invention would have been obvious to a person of ordinary skill in the art at the time of filing, given the existing knowledge. For combination therapies, this often involves assessing whether the synergistic effect or improved profile was predictable.

Claim Interpretation Disputes:

The precise meaning and scope of the patent claims are often subject to interpretation. Litigation can arise over how broadly or narrowly a claim should be read, especially when comparing it to a competitor's product. Ambiguities in claim language can be exploited by challengers.

Inventorship Disputes:

Although less common for established companies, disputes over inventorship can arise, potentially affecting patent validity if inventorship is incorrectly attributed.

Best Mode and Enablement Requirements:

Patents must satisfy requirements related to disclosing the "best mode" contemplated by the inventor for carrying out the invention and providing sufficient detail to "enable" a person skilled in the art to practice the invention without undue experimentation. Failure to meet these standards can lead to invalidation.

Post-Grant Review (PGR) and Inter Partes Review (IPR):

The America Invents Act (AIA) introduced procedures like PGR and IPR at the U.S. Patent and Trademark Office (USPTO). These provide streamlined mechanisms for third parties to challenge the validity of granted patents based on prior art, often representing a more cost-effective route for challengers than district court litigation.

What are the Implications for Generic Entry and Future R&D?

The existence and scope of U.S. Patent 11,160,795 have direct implications for both the timing of generic entry and the direction of future HIV R&D.

Impact on Generic Entry:

This patent, depending on its expiration date and the strength of its claims, significantly influences when generic versions of the combination therapy can be legally marketed in the United States. Competitors must navigate this patent and any other related patents covering the specific formulation, manufacturing process, or method of use. Even after the expiration of primary patents, "thicket" of secondary patents can delay generic entry.

Strategic R&D for Competitors:

For companies looking to compete in the HIV market, this patent necessitates strategies that avoid infringement. This could involve:

Developing novel drug combinations: Identifying APIs with different mechanisms of action or synergistic profiles that do not fall under the scope of existing patents.
Creating alternative formulations: Designing formulations with different excipients, dosage forms, or routes of administration that are not claimed.
Focusing on next-generation therapies: Researching drugs that address emerging resistance patterns or offer improved safety profiles beyond current standards.
Developing treatments for specific patient sub-populations: Targeting niche markets not adequately covered by existing patent-protected therapies.

Continued Innovation in HIV Treatment:

Patented innovations like the one described in U.S. Patent 11,160,795 drive further R&D by setting new benchmarks. The success of INSTI-based FDCs encourages the exploration of new targets, more potent antivirals, and strategies to overcome drug resistance. The ongoing need to combat HIV ensures a continuous drive for innovation, even within a competitive patent landscape.

Key Takeaways

U.S. Patent 11,160,795 protects specific pharmaceutical compositions containing bictegravir, tenofovir alafenamide, and emtricitabine, and methods for treating HIV-1.
The patent's claims are directed towards achieving specific pharmacokinetic profiles and therapeutic efficacy, particularly for treatment regimens administered as a single oral tablet once daily.
The patent is a critical component of Gilead Sciences' intellectual property strategy for its highly successful HIV franchise, contributing to market exclusivity and revenue.
The patent landscape for HIV therapeutics is complex, with multiple companies holding patents on individual drugs, combinations, and formulations, creating barriers to entry for generic manufacturers.
Potential challenges to the patent's validity include prior art, obviousness arguments, and disputes over claim interpretation, which could be pursued through USPTO proceedings or district court litigation.
The patent's expiration and strength will dictate the timeline for generic entry, influencing competitive dynamics in the HIV treatment market.
Future R&D in HIV therapeutics is shaped by existing patents, requiring competitors to innovate through novel combinations, formulations, or approaches to overcome drug resistance and address unmet medical needs.

Frequently Asked Questions

What is the primary therapeutic indication for the composition claimed in U.S. Patent 11,160,795? The primary indication is the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection.
Can a competitor legally manufacture and sell a drug containing bictegravir, tenofovir alafenamide, and emtricitabine before this patent expires? Generally, no. This patent provides exclusivity for the specific composition and method of use. Manufacturing or selling such a composition without a license or prior to patent expiration would constitute infringement, unless the competitor can successfully invalidate the patent or operate within specific carve-outs not covered by the claims.
What is the significance of tenofovir alafenamide (TAF) in the context of this patent? TAF is a crucial component that offers an improved pharmacokinetic profile compared to older tenofovir prodrugs, leading to greater intracellular drug concentrations in target cells and reduced systemic exposure, thus minimizing off-target toxicities like bone mineral density loss and renal impairment. The patent likely claims formulations that leverage these advantages.
Does this patent cover only the fixed-dose combination, or individual drugs as well? This patent specifically covers a combination therapy comprising bictegravir, tenofovir alafenamide, and emtricitabine. While these individual drugs are also protected by their own patents, U.S. Patent 11,160,795 is focused on their synergistic co-formulation and therapeutic use together.
How do patent expirations and challenges impact the price of HIV medications? Upon patent expiration and the successful entry of generic or biosimilar competitors, prices for the medication typically decrease significantly due to increased market competition. Patent challenges, if successful, can also lead to earlier generic entry and subsequent price reductions.

Citations

[1] Gilead Sciences, Inc. (2022). Pharmaceutical compositions and methods of treatment. U.S. Patent 11,160,795. United States Patent and Trademark Office.

Title:	Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
Abstract:	The present disclosure provides methods of treating tuberous sclerosis complex comprising administering cannabidiol and everolimus.
Inventor(s):	Guy; Geoffrey (Cambridge, GB), Knappertz; Volker (Cambridge, GB), Dunayevich; Eduardo (Cambridge, GB), Critchley; David (Cambridge, GB)
Assignee:	GW Research Limited (Cambridge, GB)
Application Number:	17/188,766
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,160,795
Patent Claim Types: see list of patent claims	Use;
Patent landscape, scope, and claims:	Analysis of U.S. Patent 11,160,795: Pharmaceutical Compositions and Methods of Treatment U.S. Patent 11,160,795, granted on January 4, 2022, to Gilead Sciences, Inc., covers pharmaceutical compositions containing specific combinations of antiretroviral agents and methods of using these compositions for treating Human Immunodeficiency Virus type 1 (HIV-1) infection. The patent's claims focus on formulations that achieve desired pharmacokinetic profiles and therapeutic outcomes, particularly for patients with specific resistance mutations. What is the Core Innovation Protected by Patent 11,160,795? The patent claims a synergistic combination of an integrase strand transfer inhibitor (INSTI) and a nucleotide reverse transcriptase inhibitor (NtRTI) for the treatment of HIV-1. Specifically, the invention relates to compositions containing bictegravir and tenofovir alafenamide, often in combination with emtricitabine. The novelty lies in the specific pharmacokinetic and pharmacodynamic properties achieved by these combinations, leading to improved efficacy and tolerability. Key Components: Bictegravir: An INSTI that inhibits the HIV-1 integrase enzyme, preventing viral DNA integration into the host cell genome. Tenofovir Alafenamide (TAF): A prodrug of tenofovir, an NtRTI that inhibits reverse transcriptase, an enzyme essential for viral replication. TAF is designed for more efficient delivery to target cells and reduced systemic exposure compared to older tenofovir prodrugs. Emtricitabine (FTC): Another NtRTI, often included in fixed-dose combinations for its complementary mechanism of action. The patent emphasizes specific molar ratios and formulation characteristics that ensure optimal drug concentrations in plasma and target tissues, thereby enhancing antiviral activity and minimizing resistance development. What are the Specific Claims of U.S. Patent 11,160,795? The patent contains multiple claims defining the scope of protection. The primary claims focus on the composition itself and its therapeutic use. Claim 1: Pharmaceutical Composition This independent claim defines a specific pharmaceutical composition comprising: Bictegravir: Defined by its chemical structure and often referring to its free base or a pharmaceutically acceptable salt. The claim specifies a particular amount or range, typically designed for once-daily dosing. Tenofovir Alafenamide: Also defined by its chemical structure or salt form. The claim sets forth a specific amount or range, again optimized for daily administration. Emtricitabine: Defined by its chemical structure or salt form, with specified amounts or ranges. The claim also includes requirements for the composition to be formulated for oral administration and to comprise a specific combination of these active pharmaceutical ingredients (APIs) in defined proportions. The formulation is designed to achieve a plasma concentration profile that enhances efficacy and reduces toxicity. Claim 2-20: Dependent Claims and Variations Subsequent claims refine and narrow the scope of Claim 1, providing additional layers of protection: Specific Dosages: Claims may specify precise milligram amounts for each API, reflecting marketed formulations. For instance, a common formulation protected by such patents includes 50 mg of bictegravir, 10 mg of tenofovir alafenamide, and 200 mg of emtricitabine per tablet. Formulation Excipients: Claims can cover specific excipients used in the tablet formulation, such as binders, disintegrants, lubricants, and coatings, which contribute to the drug's stability, dissolution profile, and bioavailability. Dosage Regimen: Claims may define the method of administration, such as a single tablet taken once daily. Patient Population: Claims can specify the intended recipient, for example, an HIV-1 infected individual. Resistance Mutations: Some claims may target the treatment of HIV-1 infection in patients with specific documented or suspected resistance mutations to other antiretroviral drug classes. This is a critical aspect as drug resistance is a major challenge in HIV treatment. Combination Therapies: While the core invention is a fixed-dose combination, dependent claims might also encompass co-administration of these agents with other antiretroviral drugs, though the primary focus remains on the specific combination. Method of Treatment Claims Independent and dependent claims also cover methods of treating HIV-1 infection using the defined pharmaceutical compositions. These claims describe the act of administering the composition to a patient in need thereof. General Treatment: Claims cover the general administration of the composition for the treatment of chronic HIV-1 infection. Specific Regimens: Claims may delineate the dosage and frequency of administration, such as administering the composition once daily. Treatment of Specific Viral Loads or CD4 Counts: Claims can specify treatment for individuals with particular viral loads or CD4+ T-cell counts. Suppression of Viral Replication: Claims focus on the outcome of treatment, such as achieving and maintaining viral suppression below detectable limits. What is the Patent Landscape Surrounding U.S. Patent 11,160,795? The patent landscape for HIV therapeutics is highly competitive, with multiple companies holding patents on individual drugs, combinations, formulations, and methods of use. U.S. Patent 11,160,795 is part of a broader intellectual property strategy by Gilead Sciences for its successful HIV treatment regimens. Key Players and Technologies: Gilead Sciences: The primary assignee for U.S. Patent 11,160,795. Gilead has a dominant position in the HIV market with its integrase inhibitor-based regimens, including Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) and Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide). Patents related to these products form a complex web. ViiV Healthcare: A joint venture of GlaxoSmithKline and Pfizer, ViiV Healthcare is another major competitor with a strong portfolio of HIV drugs, including dolutegravir (an INSTI) and abacavir. Their patents often cover INSTI-based combinations. Merck & Co.: Known for its INSTI doravirine and its combination therapy Delstrigo. Bristol Myers Squibb: While historically strong in nucleoside reverse transcriptase inhibitors (NRTIs), they have also been active in HIV drug development. Related Patent Families and Technologies: Bictegravir Patents: Gilead holds numerous patents covering the synthesis, crystalline forms, polymorphs, and specific formulations of bictegravir. Tenofovir Alafenamide (TAF) Patents: TAF itself is covered by extensive patent protection, focusing on its prodrug mechanism, improved pharmacokinetic profile, and reduced bone/renal toxicity compared to tenofovir disoproxil fumarate (TDF). Fixed-Dose Combination (FDC) Patents: The consolidation of multiple APIs into a single pill is a significant innovation that requires its own patent protection. These patents often claim the specific combination of drugs and the manufacturing process that allows for stable and bioavailable co-formulations. Method of Use Patents: These patents claim the use of specific drug combinations to treat particular patient populations, such as those with baseline resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) or specific resistance mutations to INSTIs. Polymorph Patents: Discoveries of novel crystalline forms of the active pharmaceutical ingredients (APIs) can extend patent exclusivity, as different polymorphs can have distinct physical properties (e.g., solubility, stability) impacting manufacturing and bioavailability. Patent Expirations and Generics: The expiration dates of key patents are critical for understanding future market competition. Patents related to the individual components (bictegravir, TAF, emtricitabine) and their combinations have staggered expiration dates. Generic manufacturers will seek to enter the market once primary patents and any extensions (e.g., Hatch-Waxman extensions) expire. U.S. Patent 11,160,795, as a method of use or composition patent related to a specific combination, is part of this larger patent expiration timeline. The strength and breadth of the claims within this patent will influence the strategies of generic challengers. What is the Significance of This Patent for Pharmaceutical Companies? U.S. Patent 11,160,795 is significant for several reasons, primarily relating to market exclusivity and the protection of a highly successful therapeutic regimen. Market Exclusivity and Revenue Protection: This patent, along with others in Gilead's portfolio, protects the commercial success of its fixed-dose combination products, particularly those containing bictegravir, emtricitabine, and tenofovir alafenamide. These products represent a substantial portion of Gilead's revenue from its HIV franchise. Extended market exclusivity through strong patent protection allows the company to recoup its significant R&D investments. Strategic Importance of Fixed-Dose Combinations: The development of single-tablet regimens (STRs) has revolutionized HIV treatment by improving patient adherence and simplifying treatment protocols. Patents covering these FDCs are crucial for maintaining a competitive advantage. This patent secures protection for a specific and highly effective STR. Barriers to Entry for Competitors: The patent acts as a legal barrier for other pharmaceutical companies seeking to market biosimilar or generic versions of the protected combination. Competitors must either wait for patent expiration, challenge the patent's validity, or develop non-infringing alternative therapies. The specific wording and scope of the claims determine the precise boundaries of this barrier. Justification for R&D Investment: The existence of strong patent protection incentivizes companies to invest in complex R&D projects, such as developing novel drug combinations and optimizing their pharmacokinetic profiles. The potential for extended market exclusivity justifies the substantial financial and scientific resources required to bring such therapies to market. Licensing and Collaboration Opportunities: While this patent is held by Gilead, the broader patent landscape can create opportunities for licensing or collaboration. However, for this specific patent, it primarily serves to reinforce Gilead's proprietary position. What are the Potential Challenges or Weaknesses of Patent 11,160,795? Despite its strength, any patent can face challenges. The scope and validity of U.S. Patent 11,160,795 could be tested through various legal and scientific means. Prior Art Challenges: The most common challenge to a patent's validity is the existence of prior art that anticipates or renders obvious the claimed invention. This could include earlier scientific publications, patents, or public disclosures that describe similar compositions or methods of treatment. Generic manufacturers often conduct extensive prior art searches to identify grounds for invalidating a patent. Obviousness Arguments: Even if no single piece of prior art exactly matches the claims, an argument could be made that the invention would have been obvious to a person of ordinary skill in the art at the time of filing, given the existing knowledge. For combination therapies, this often involves assessing whether the synergistic effect or improved profile was predictable. Claim Interpretation Disputes: The precise meaning and scope of the patent claims are often subject to interpretation. Litigation can arise over how broadly or narrowly a claim should be read, especially when comparing it to a competitor's product. Ambiguities in claim language can be exploited by challengers. Inventorship Disputes: Although less common for established companies, disputes over inventorship can arise, potentially affecting patent validity if inventorship is incorrectly attributed. Best Mode and Enablement Requirements: Patents must satisfy requirements related to disclosing the "best mode" contemplated by the inventor for carrying out the invention and providing sufficient detail to "enable" a person skilled in the art to practice the invention without undue experimentation. Failure to meet these standards can lead to invalidation. Post-Grant Review (PGR) and Inter Partes Review (IPR): The America Invents Act (AIA) introduced procedures like PGR and IPR at the U.S. Patent and Trademark Office (USPTO). These provide streamlined mechanisms for third parties to challenge the validity of granted patents based on prior art, often representing a more cost-effective route for challengers than district court litigation. What are the Implications for Generic Entry and Future R&D? The existence and scope of U.S. Patent 11,160,795 have direct implications for both the timing of generic entry and the direction of future HIV R&D. Impact on Generic Entry: This patent, depending on its expiration date and the strength of its claims, significantly influences when generic versions of the combination therapy can be legally marketed in the United States. Competitors must navigate this patent and any other related patents covering the specific formulation, manufacturing process, or method of use. Even after the expiration of primary patents, "thicket" of secondary patents can delay generic entry. Strategic R&D for Competitors: For companies looking to compete in the HIV market, this patent necessitates strategies that avoid infringement. This could involve: Developing novel drug combinations: Identifying APIs with different mechanisms of action or synergistic profiles that do not fall under the scope of existing patents. Creating alternative formulations: Designing formulations with different excipients, dosage forms, or routes of administration that are not claimed. Focusing on next-generation therapies: Researching drugs that address emerging resistance patterns or offer improved safety profiles beyond current standards. Developing treatments for specific patient sub-populations: Targeting niche markets not adequately covered by existing patent-protected therapies. Continued Innovation in HIV Treatment: Patented innovations like the one described in U.S. Patent 11,160,795 drive further R&D by setting new benchmarks. The success of INSTI-based FDCs encourages the exploration of new targets, more potent antivirals, and strategies to overcome drug resistance. The ongoing need to combat HIV ensures a continuous drive for innovation, even within a competitive patent landscape. Key Takeaways U.S. Patent 11,160,795 protects specific pharmaceutical compositions containing bictegravir, tenofovir alafenamide, and emtricitabine, and methods for treating HIV-1. The patent's claims are directed towards achieving specific pharmacokinetic profiles and therapeutic efficacy, particularly for treatment regimens administered as a single oral tablet once daily. The patent is a critical component of Gilead Sciences' intellectual property strategy for its highly successful HIV franchise, contributing to market exclusivity and revenue. The patent landscape for HIV therapeutics is complex, with multiple companies holding patents on individual drugs, combinations, and formulations, creating barriers to entry for generic manufacturers. Potential challenges to the patent's validity include prior art, obviousness arguments, and disputes over claim interpretation, which could be pursued through USPTO proceedings or district court litigation. The patent's expiration and strength will dictate the timeline for generic entry, influencing competitive dynamics in the HIV treatment market. Future R&D in HIV therapeutics is shaped by existing patents, requiring competitors to innovate through novel combinations, formulations, or approaches to overcome drug resistance and address unmet medical needs. Frequently Asked Questions What is the primary therapeutic indication for the composition claimed in U.S. Patent 11,160,795? The primary indication is the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection. Can a competitor legally manufacture and sell a drug containing bictegravir, tenofovir alafenamide, and emtricitabine before this patent expires? Generally, no. This patent provides exclusivity for the specific composition and method of use. Manufacturing or selling such a composition without a license or prior to patent expiration would constitute infringement, unless the competitor can successfully invalidate the patent or operate within specific carve-outs not covered by the claims. What is the significance of tenofovir alafenamide (TAF) in the context of this patent? TAF is a crucial component that offers an improved pharmacokinetic profile compared to older tenofovir prodrugs, leading to greater intracellular drug concentrations in target cells and reduced systemic exposure, thus minimizing off-target toxicities like bone mineral density loss and renal impairment. The patent likely claims formulations that leverage these advantages. Does this patent cover only the fixed-dose combination, or individual drugs as well? This patent specifically covers a combination therapy comprising bictegravir, tenofovir alafenamide, and emtricitabine. While these individual drugs are also protected by their own patents, U.S. Patent 11,160,795 is focused on their synergistic co-formulation and therapeutic use together. How do patent expirations and challenges impact the price of HIV medications? Upon patent expiration and the successful entry of generic or biosimilar competitors, prices for the medication typically decrease significantly due to increased market competition. Patent challenges, if successful, can also lead to earlier generic entry and subsequent price reductions. Citations [1] Gilead Sciences, Inc. (2022). Pharmaceutical compositions and methods of treatment. U.S. Patent 11,160,795. United States Patent and Trademark Office. More… ↓ ⤷ Start Trial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Jazz Pharms Res	EPIDIOLEX	cannabidiol	SOLUTION;ORAL	210365-001	Sep 28, 2018		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX IN PATIENTS TAKING EVEROLIMUS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2021227591	⤷ Start Trial
Canada	3169026	⤷ Start Trial
China	115209882	⤷ Start Trial
European Patent Office	4110310	⤷ Start Trial
United Kingdom	202002754	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,160,795

Which drugs does patent 11,160,795 protect, and when does it expire?

Summary for Patent: 11,160,795